Özet:

Prostate cancer is the second most common type of cancer amongst men worldwide. The morbidity and mortality of prostate cancer has increased recently. Although many alternative approaches have been tried to be developed for the treatment, prostate cancer still has a poor prognosis and high mortality rates. Myricetin is a natural flavonoid compound of interest for its anticancer properties. In vitro and in vivo studies show that myricetin effectively impedes prostate cancer through several mechanisms. The aim of this study was to determine the effects of increasing doses of myricetin on the viability of LNCaP cells, an androgen receptor-dependent human prostate cancer cell line, and to determine the expression levels of the apoptosis-related BAX and BCL2 genes. LNCaP cells were incubated with myricetin at concentrations of 10 μM, 25 μM, 50 μM, 100 μM, 150 μM for 24 and 48 hours and alterations in cell viability were determined by 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl) )-2Htetrazolium-5-carboxanilide (XTT) method and IC50 values were calculated. Changes in BAX and BCL2 gene expressions were investigated by Real-Time PCR and the data was analysed using ΔΔCT method. It was shown that myricetin decreased LNCaP cell viability at all doses used compared to the control, and the IC50 value was determined as 123.76 μM for the 24th hour and 84.79 μM for the 48th hour. In addition, it was observed that myricetin administration increased apoptosis associated BAX gene expression at a statistically significant level, while it was decreasing BCL2 gene expression. The antiproliferative and apoptotic effects of myricetin on LNCaP cells need to be investigated in more detail.